Blog Archives

Supergen $SUPG and Astex ASCO Presentations

4/26/2011

Supergen will make the following presentaitons at ASCO (note I did not locate any presentations by its proposed merger partner Astex):

Saturday June 4th: Oral Presentation
Abstract #5011 5:30 PM - 5:45 PM
"A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC)."
Daniela Matei, MD

Monday June 6th: Poster Presentation
Abstract #8530
"Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM)."
Jan H. Beumer, PhD, PharmD

Monday June 6th: Oral Presentation
Abstract #6504 10:45 AM - 11:00 AM
"Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML."
Xavier G. Thomas, MD, PhD

Monday June 6th: Poster Presentation
Abstract #6537
"A phase II study with decitabine, low-dose cytarabine and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia or acute myeloid leukemia in patients with significant comorbidities."
James Butera, MD

Monday June 6th: Poster Presentation
Abstract #3074
"Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens."
Kamalesh K. Sankhala, MD, MBBS

0 Comments

Myrexis $MYRX ASCO Presentation

4/26/2011

0 Comments

Myrexis will present the following poster on Azixa:

Saturday June 4th: Poster Presentation
Abstract #2088
"Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naïve to treatment with bevacizumab."
Lyndon J. Kim, MD

0 Comments

Ligand $LGND ASCO Presentations

4/26/2011

0 Comments

Ligand's partners will make the following presentations at ASCO:

Saturday June 4th: Poster Presentation
Abstract #8025
"Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)."
Michael Wang, MD

Saturday June 4th: Poster Presentation
Abstract #8026
"The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naïve relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study"
A. K. Stewart, MBChB

Saturday June 4th: Poster Presentation
Abstract #8027
"PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis."
David S. Siegel, MD, PhD

Saturday June 4th: Poster Presentation
Abstract #8028
"Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM)."
Jackie Szymonifka

Monday June 6th: Poster Presentation
Abstract #6623
"Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL."
Joseph M. Flynn, DO

Monday June 6th: Poster Presentation
Abstract #TPS225
"A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM)."
Philippe Moreau, MD

Monday June 6th: Poster Presentation
Abstract #6632
"Effects of eltrombopag on human cord blood hematopoietic stem cell/primitive progenitor cell expansion."
Hongliang Sun, PhD

Monday June 6th: Poster Presentation
Abstract #6571
"Interim PK analysis results of a phase IIa, open-label, randomized, pharmacokinetic comparative, cross-over study of melphalan HCl for injection (propylene glycol-free) and alkeran for injection for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation."
Omar S. Aljitawi, MD

Monday June 6th: Poster Presentation
Abstract #3080
"A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results."
Monica M. Mita, MD

0 Comments

Isis Pharma $ISIS ASCO presentations

4/26/2011

0 Comments

Isis Pharma will have the following presentations at ASCO:

Saturday June 4th: Oral Presentation
Abstract #4502 2:15 PM - 2:30 PM
"An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model."
Hiroaki Matsumoto, MD

Sunday June 5th: Poster Presentation
Abstract #4592
"Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC)."
Pawel J. Wiechno, MD, PhD

Sunday June 5th: Poster Presentation
Abstract #4573
"CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer."
Francois Lamoureux, PhD

0 Comments

Infinity Pharma $INFI ASCO presentations

4/26/2011

0 Comments

Infinity Pharma will make several presentations at ASCO:

Saturday June 4th: Poster Presentation
Abstract #3014
"A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors."
Charles M. Rudin, MD, PhD

Saturday June 4th: Poster Presentation
Abstract #4114
"The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer."
Joe Stephenson, MD

Monday June 6th: Poster Presentation
Abstract #590
"Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer."
Shanu Modi, MD

Monday June 6th: Poster Presentation
Abstract #7516
"Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC)."
Gregory J. Riely, MD, PhD

Note: I could not locate any presentations regarding INFI's second HSP90 inhibitor IPI-493

0 Comments

<<Previous

Supergen $SUPG and Astex ASCO Presentations

Myrexis $MYRX ASCO Presentation

Ligand $LGND ASCO Presentations

Isis Pharma $ISIS ASCO presentations

Infinity Pharma $INFI ASCO presentations

Categories

Archives